D. Semiond

发表

An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors

J. Machiels, P. Maison-Blanche, S. Dakhil, 2014, Cancer Chemotherapy and Pharmacology.

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

P. Vrignaud, M. Bissery, J. Riou, 2013, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

A. Tolcher, L. Denis, M. Beeram, 2009, Clinical Cancer Research.

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

L. Nguyen, C. Veyrat‐Follet, Hoai‐Thu Thai, 2021, CPT: pharmacometrics & systems pharmacology.

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab

R. Vij, D. Atanackovic, P. Moreau, 2021, Blood Cancer Journal.

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

J. Machiels, M. Campone, X. Pivot, 2011, European journal of cancer.

Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel

P. Vrignaud, S. Sidhu, M. Bissery, 2013, Cancer Chemotherapy and Pharmacology.

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

L. Nguyen, F. Campana, D. Sémiond, 2020, CPT: pharmacometrics & systems pharmacology.

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats

S. Cisternino, J. Scherrmann, F. Bourasset, 2003, British journal of pharmacology.

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical profile of cabazitaxel

P. Vrignaud, Sunil Gupta, H. Bouchard, 2014, Drug design, development and therapy.

Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844).

A. Rak, F. Vallée, M. Lowinski, 2016, Journal of medicinal chemistry.

Novel Taxanes: Cabazitaxel Case Study

P. Vrignaud, H. Bouchard, D. Sémiond, 2012 .

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

D. Rea, D. Richel, C. Punt, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

N. Raje, S. Usmani, W. Bensinger, 2019, Blood.

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

M. Campone, P. Fumoleau, N. Isambert, 2013, BMC Cancer.

A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors.

S. Clive, Lindsay Kelly, H. Fontaine, 2015, Anti-cancer drugs.

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

M. Campone, P. Fumoleau, N. Isambert, 2013, BMC Cancer.

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors

G. Ferron, Yang Dai, D. Sémiond, 2013, Cancer Chemotherapy and Pharmacology.

Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.

J. Pierga, V. Girre, V. Diéras, 2013, European journal of cancer.

Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

Y. Shitara, C. Veyrat‐Follet, Hoai‐Thu Thai, 2023, CPT: pharmacometrics & systems pharmacology.

PF645 EXPOSURE-RESPONSE ANALYSIS & DISEASE MODELING FOR SELECTION OF OPTIMAL DOSING REGIMEN OF ISATUXIMAB AS SINGLE AGENT IN PATIENTS WITH MULTIPLE MYELOMA

L. Nguyen, C. Veyrat‐Follet, Hoai‐Thu Thai, 2019, HemaSphere.

Abstract 2908: A first-in-human phase I study of SAR650984, a humanized anti-CD38 antibody in patients with CD38+ hematological malignancies: Preliminary PK and PD results of escalation phase

C. Veyrat‐Follet, H. Guillemin, D. Valente, 2014 .

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

L. Nguyen, C. Veyrat‐Follet, Hoai‐Thu Thai, 2022, CPT: pharmacometrics & systems pharmacology.

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

C. Veyrat‐Follet, Hoai‐Thu Thai, D. Sémiond, 2021, British journal of clinical pharmacology.

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis

M. Dimopoulos, P. Richardson, P. Moreau, 2020, Leukemia.

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

M. Piccart, A. V. van Oosterom, A. Awada, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results.

J. Machiels, M. Campone, X. Pivot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.

C. Sessa, Joshua A. Bauer, C. Monnerat, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I dose-ﬁnding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours

M. Piccart, A. Awada, R. Maes, 2006 .

Identification and Isotopic Analysis of Safranal from Supercritical Fluid Extraction and Alcoholic Extracts of Saffron

M. Désage, H. Casabianca, J. Brazier, 1996 .

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein

B. Sikic, D. Gianolio, D. Weitz, 2018, Cancer Chemotherapy and Pharmacology.

A bridging study of fananserin in schizophrenic patients.

N. Cutler, J. Sramek, J. Hourani, 1998, Psychopharmacology bulletin.

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

A. Oriol, P. Moreau, E. Ocio, 2021, Blood.

5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy

J. Machiels, M. Campone, X. Pivot, 2009 .

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as ﬁrst-line therapy for advanced colorectal cancer

D. Kerr, D. Richel, G. Groenewegen, 2005 .